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Transforming mutants of the p53 tumor suppressor gene can positively regulate transcription from several
promoters that do not contain known p53 binding sites. Here, we report the identification of a novel p53
binding site in the human immunodeficiency virus long terminal repeat that specifically mediates mutant p53
transactivation. This DNA element was bound by endogenous Jurkat p53 when these cells were stimulated by
tumor necrosis factor. Mutation of this sequence inhibited p53 transactivation and tumor necrosis factor
inducibility of the human immunodeficiency virus type 1 long terminal repeat. In addition, this DNA element
was found to be sufficient to confer mutant p53 responsiveness on a heterologous minimal promoter. It has
been hypothesized that transforming mutants of p53 represent a proliferative conformational stage that can be
adopted by the native protein under stimulation by growth factors. The data presented suggest that prolifer-
ative and antiproliferative p53 conformations recognize different DNA binding sites in order to mediate distinct
biological functions. Thus, transforming mutants of p53 that fold into the proliferative conformation would
favor proliferative over antiproliferative functions.
The p53 protein plays a critical role in the control of cellular
proliferation, and inactivation of p53 is a key event in the
induction of malignant transformation (28, 36). This inactiva-
tion may occur by several mechanisms, including viral inser-
tion, gene rearrangements or deletions, overexpression of p53-
associated proteins, and binding to viral proteins (54). More
than 60% of human tumors contain elevated levels of mutant
p53 protein (28, 36). These mutations are mostly single mis-
sense mutations within the coding sequence (46, 54).
Although the mechanism of action of p53 is not fully under-
stood, many studies have implicated p53 in the regulation of
transcription. Wild-type p53 is known to bind specific DNA
sequences (3, 24, 33, 51), and a consensus p53 binding site has
been identified (18). p53 activates transcription of reporter
genes that contain multiple copies of the wild-type p53 binding
site (20, 24, 33). Importantly, it has been shown that p53 also
regulates the expression of several cellular promoters (1–3, 31,
68, 69, 71, 72). Mutated forms of p53 can transactivate certain
promoters, but no DNA binding site for p53 has been shown to
be responsible for this effect (12, 16). The amino terminus of
p53 is highly acidic and functions as a transcriptional activation
domain (21). MDM2, a p53-associated protein, has been
shown to inhibit p53 transcriptional activity by binding to this
activation domain (42). Evidence indicating that the wild-type
p53 binding activity resides in the highly conserved central
region of the protein has been recently reported (3, 10, 13, 49,
67). Interestingly, the vast majority of the transforming muta-
tions are located in this region (see reference 46 and references
therein).
Most point mutations inactivate p53 tumor suppressor func-
tion, and some may also induce p53 to acquire oncogenic
properties and promote proliferation (10, 51). The localization
of the mutations may reflect a selective pressure in tumors to
activate the cell’s proliferative mechanisms or to inactivate
tumor suppressor functions (46). The latter hypothesis is con-
sistent with the generalization that the mechanism of action of
transforming mutants of p53 is to block the site-specific DNA
binding activity of wild-type p53. Indeed, the p53 mutant forms
inhibit wild-type p53-regulated expression of genes containing
p53 consensus binding sites (33). However, it has been shown
that expression of mutated p53 in human cell lines that com-
pletely lacked endogenous p53 expression conferred a growth
advantage to the cells (10). This study indicates that mecha-
nisms other than a blockage of wild-type p53 binding activity
may be implicated in the proliferative effects of mutant p53
protein forms. In support of this point, most tumors involving
p53 have one deleted p53 allele and one mutated p53 allele
(46).
Point mutations can alter the tertiary structure of p53, thus
affecting its reactivity to specific anti-p53 monoclonal antibod-
ies. Changes in antibody specificity correlate with changes in
presumed p53 functions. For example, p53 forms that express
the PAb 421 or PAb 122 epitope are associated with cell
growth and p53 from growth-arrested cells displays the PAb
246 and PAb 1620 epitopes (62, 63). In cells that express
wild-type and mutant p53 simultaneously, wild-type p53 asso-
ciated with mutant p53 adopts the PAb 240 mutant conforma-
tion and is no longer able to induce growth arrest (62). To
explain how p53 may both enhance and inhibit cell prolifera-
tion, it has been postulated that p53 exists in two alternative
protein conformations, the so-called antiproliferative and pro-
liferative forms (see references 39, 41, and 62 and references
therein). In response to growth stimuli, wild-type p53 appar-
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ently undergoes a conformational change during the G1 phase
of the cell cycle and adopts a proliferative or mutant-like con-
formation. The forces that may drive p53 from a proliferative
to a nonproliferative form and vice versa are unclear, although
it has been suggested that phosphorylation plays an important
role in stabilizing the antiproliferative conformation (62, 65).
The identification of p53 in a mutant-like conformation in
acute myeloid leukemia cells was interpreted as involving mu-
tations in the p53 gene. However, a survey of p53 variants in
acute myeloid leukemia patients revealed that 75% of the p53
samples immunoprecipitated by PAb 240 (mutant-like confor-
mation) contained no mutations (73). Thus, alteration of p53
conformation, rather than acquisition of point mutations, may
be the mechanism underlying an altered p53 tumor suppressor
function in most cases of acute myeloid leukemia or blast crisis
of chronic myeloid leukemia. In addition, this PAb 240 epitope
has been demonstrated in normal lymphocytes induced to pro-
liferate (73) and in p53 coimmunoprecipitated with Sp1 in
erythroleukemia cells (6).
Here, we report the identification of a p53-specific binding
site in the human immunodeficiency virus (HIV) long terminal
repeat (LTR) which mediates tumor necrosis factor (TNF)
induction of gene expression. This DNA element was bound by
endogenous Jurkat p53 (antibody 240 positive) when cells were
stimulated by TNF. Transfection studies demonstrate that mu-
tant p53 specifically transactivates gene expression through this
novel DNA element. These data suggest that p53 plays an
important role in the transcriptional activation of the HIV
LTR by TNF. In addition, the data support a model in which
proliferative and antiproliferative forms of p53 bind to differ-
ent DNA elements and therefore differentially regulate gene
expression.
MATERIALS AND METHODS
Electrophoretic mobility shift assays (EMSAs). The LTR A and B sequences
used were (double-stranded) tcgacGGGACTTTCCAGGGAGGCGTGGCCTG
(LTR A) and CAGGGAGGCGTGGCCTGGGCGGGACTGGGG (LTR B).
SalI sites were added to the LTR A sequence for subcloning purposes. Other
oligonucleotide sequences used were as follows (duplexes): the p53 site, CAGG
GAGGGCGTGGCCTGGGTTTTACTGGGG; the Sp1 site, CAGGGAGGCT
TTTCCTGGGCGGGACTGGGG; LTR B GGGAGGm, CATTTTGGCGTG
GCCTGGGCGGGACTGGGG; p53kB, cgacGGATTGGGGTTTTCCCCTCC
CATGTGCTCAG, containing the kB site in the human p53 promoter (61); IC,
TGGGCGGAGTGGCCTTCTGTGGACGAAT, containing the Sp1 site in the
HLA-DRA promoter (7); RGC, tcgacCTTGCCTGGACT TGCCTGG, and
MCK, TGGCCGGGGCCTGCCTCTCTCTGCCTCTGA, with the p53 binding
site of the muscle creatine kinase (MCK) promoter (71); MgBH, tcgacGACAC
TGGTCACACTTGGCTGCTTAGGAATG (23); and SRE and MRE, which
were described previously (66). DNA oligonucleotides were prepared with an
Applied Biosystems 391EP DNA synthesizer by the phosphoramidite method
and were purified by denaturing polyacrylamide gel electrophoresis (PAGE) and
Sep-Pak C18 cartridges (Waters Associates). Gel shift mobility assays were
prepared as follows. In a 10-ml reaction volume containing the binding reaction
buffer (20 mM HEPES [N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic acid;
pH 7.5], 400 mM NaCl, 1 mM ZnCl2, 1 mM EDTA, 1 mM b-mercaptoethanol,
1 mM phenylmethylsulfonyl fluoride, 5% glycerol), 5 mg of poly(dIdC) z (dIdC)
and 1 mg of nuclear extract protein per reaction were used, with an incubation
time of 20 min. The reaction mixtures were loaded into a 3.8% polyacrylamide
gel previously prerun for 15 min at 200 V (65). Electrophoresis was performed
at 20 V/cm in 22 mM Tris borate buffer with 0.5 mM EDTA. The gels were dried
and exposed to film overnight at 2708C with an intensifying screen. The probes
used in the binding assays were labeled with polynucleotide kinase and
[g-32P]ATP (.4,500 Ci/mmol; Amersham). Typically, the labeled probes were
purified with Elutip-D columns (Schleicher and Schuell) according to the direc-
tions of the manufacturer. Competition experiments were carried out with a fixed
concentration of the probe and a 200- to 500-fold excess of the nonlabeled
competitor.
Methylation interference footprinting. Probes for methylation interference
footprinting were prepared as follows. Single-stranded oligonucleotides contain-
ing the sequence 59-tcgaGGGACTTTCCAGGGAGGCGTGGCCTG-39 and its
complementary sequence were phosphorylated independently and radiolabeled
as indicated below. Nonradiolabeled complementary strands were added and
annealed, and duplex oligonucleotides were methylated in 200 ml of a 1:100
dilution of dimethylsulfate for 15 min. Preparative gels for EMSA were prepared
by scaling up by 10-fold gel shift assay reactions with probes partially methylated
with dimethylsulfate. After preparative gel shift, bands containing free and
bound probes were excised and eluted overnight in 2 ml of Tris-HCl (100 mM,
pH 7.5)–EDTA (1 mM)–200 mM NaCl. DNA was purified by Elutip-D columns
(Schleicher & Schuell), ethanol precipitated, and cleaved by incubation in 100 ml
of 10% piperidine at 908C. Piperidine was eliminated by three rounds of evap-
oration in a speed vacuum and resuspension in 100 ml of deionized water.
Cleaved oligonucleotides were resuspended in DNA sequencing sample buffer
and resolved in a 20% denaturing polyacrylamide gel. Gels were covered with
plastic wrap and exposed to film at 2808C.
UV cross-linking. LTR A-UV, the template for UV cross-linking, was an LTR
A probe with a bromodeoxyuridine (BrdU)-for-T substitution at position 25. For
cross-linking experiments with the LTR B probe, a BrdU-for-T substitution was
introduced at position 11. Tenfold scale-up EMSA reaction mixtures were pre-
pared as indicated above and irradiated for 20 min at room temperature with
312-nm UV light. The reaction mixtures were loaded onto 3.8% polyacrylamide
gels and run as indicated. Gels were covered with plastic wrap and exposed to
film. DNA-protein complexes were excised and loaded onto a sodium dodecyl
sulfate (SDS)–10% polyacrylamide gel. Gels were run with a Bio-Rad electro-
phoresis system, dried, and exposed to film. In cross-linking–immunoprecipita-
tion studies, 250 ml of immunoprecipitation buffer was added and the immuno-
precipitation was carried out as indicated below.
Biotinylated DNA affinity protein purification. Nuclear extracts from TNF-
treated cells (100 mg) were incubated with 100 ng of a biotinylated probe in the
presence of 100 mg of poly (dIdC) z (dIdC), for 20 min at room temperature.
Streptavidin MagneSphere beads (Promega; 150 ml) were added, and the mix-
ture was incubated for an additional 15 min before precipitation through a
magnetic field. The pellet was resuspended in 250 ml of phosphate-buffered
saline (PBS) with 10 mg of poly(dIdC) z (dIdC) before being reprecipitated. The
second pellet was then boiled in SDS-PAGE loading buffer, and the presence of
p53 was determined by Western (immunoblot) analysis. The oligonucleotide
sequences used were (duplexes) biotin-CGGGACTTTCCAGGGAGGCGTG
GCCTG (biotin-LTR A), biotin-CAGGGAGGCGTGGCCTGGGCGGGACT
GGGG (biotin-LTR B), and biotin-CAGGGAGGCGTAAACTGGGCGGGA
CTGGGG (biotin-LTR B p53m).
Antibodies, immunoprecipitations, and Western blotting. Mouse monoclonal
anti-p53 PAb 240 and PAb 1801 and rabbit polyclonal anti-Sp1 antibodies were
purchased from Santa Cruz. Mouse monoclonal anti-p53 1620 was obtained from
Oncogene Sciences. In immunoprecipitation studies, 2 3 107 Jurkat cells were
washed twice for 10 min in 10 ml of methionine-free RPMI 1640 medium and
incubated for 1 h at 378C in 5 ml of new medium with 2.5 mCi of [35S]methionine
(1,175 Ci/mmol; NEN). Cells were collected by centrifugation and lysed in 1 ml
of immunoprecipitation buffer (PBS containing 1% Triton X-100, 0.1% SDS, 1
mM dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride) prior to centrifu-
gation at 1,500 3 g for 10 min. Cell lysates were incubated in the presence of 10
mg of the appropriate antibody at 48C for 1 h before a further 4-h incubation with
protein A/G-agarose (Promega). The immunoprecipitates were collected by cen-
trifugation at 5,000 3 g for 10 min, washed twice with 250 ml of immunoprecipi-
tation buffer, and resuspended in SDS-PAGE sample buffer which was boiled for
5 min and electrophoresed. In Western blotting assays, the electrophoresis was
carried out in 10% polyacrylamide minigels (Bio-Rad). Equal amounts of pro-
teins were assayed under all conditions, as determined by the Bradford protein
assay (Bio-Rad). Proteins were transferred to Immobilon-P membranes (Milli-
pore) and probed with anti-p53 PAb 1801 (1:500) by the manufacturers’ recom-
mended method.
Plasmids.HIV type 1 (HIV-1) LTR chloramphenicol acetyltransferase (CAT)
reporter plasmid constructs were a gift from B. Stein (56). Site-directed mutated
HIV LTR 53D CAT plasmid and minimal enhancer elements were constructed
as described previously (50). HIV LTR 53D contains the mutation ACTCGA for
GGCGTG at the HIV p53 site. 53-E1B TATA and 53D-E1B TATA contain the
HIV LTR sequences (duplex) CGCTGGGGACTTTCCAGGGAGGCGTGGC
CTGA, and CGCTGGGGACTTTCCAGGGAGACTCGAGCTGA upstream
of an E1B TATA box CAT reporter plasmid (the underlined sequence repre-
sents the wild-type or mutant p53 site). The cytomegalovirus (CMV) enhancer/
promoter-driven expression vectors (containing wild-type p53 and the tumor-
promoting p53 143ala form) and the reporter plasmid PG13 (containing 13
copies of a wild-type p53 consensus binding site) were a gift from B. Vogelstein
(33). Expression vector 53D was prepared by digestion of the CMV-p53 vector
with StuI and AccI and religation. The murine sarcoma virus LTR-driven p53
expression vectors were gifts from C. Finley (wt, 175his, 248trp, and 273his) and
G. Lozano (135val). All plasmids were prepared with Qiagen columns according
to the directions of the manufacturers.
Cell culture, cell extracts, transfections, and CAT assays.Jurkat T-leukemia cells
from the American Type Culture Collection were cultured at densities of 0.13 106
to 0.5 3 106 cells per ml in RPMI 1640 medium with glutamine and 2% fetal calf
serum (Irvine) and penicillin-streptomycin.When TNF incubations were performed,
cells were centrifuged, resuspended in new media at 1 3 106 cells per ml in the
absence or presence of 10 ng of recombinant TNF-a (rTNF-a) (Promega) per ml,
and incubated for 30 to 45 min. The incubations were stopped by centrifugation, and
the cells were processed for immunoprecipitations or preparation of nuclear ex-
tracts. Nuclear cell extracts were prepared as described previously (4), but a
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final phenylmethylsulfonyl fluoride concentration of 1 mM was used. Extracts
were divided into aliquots and stored at 2808C. For transfection experiments,
Jurkat and Akata cells were cultured in RPMI 1640 medium plus glutamine,
penicillin-streptomycin, and 10% fetal calf serum. Cells were transfected by
electroporation (300 V, 960 mF; Bio-Rad Electroporator) at 5 million cells per
0.5 ml of PBS and resuspended in 10 ml of medium. Incubations were carried out
for 24 to 48 h. Cells were lysed by 3-s ultrasonic vibrations at 48C with a Branson
Sonifier at setting 3. Equal amounts of protein, as determined by the Bradford
assay (Bio-Rad), were then analyzed for CAT activity by fluor diffusion assay
(44).
RESULTS
Identification of a TNF-responsive region and TNF-induc-
ible complexes (TICs) on the HIV LTR. The ability of HIV-1 to
replicate in T lymphocytes and mononuclear phagocytes is
strongly influenced by several immunoregulatory cytokines.
However, only TNF-a or TNF-b has been shown thus far to
trigger viral expression in both T cells and mononuclear phago-
cytes (5). As a step forward in elucidating the mechanism of
HIV-1 induction by TNF, we attempted to define the DNA-
protein interactions that mediate the transactivation of the
HIV-1 LTR by this cytokine. Jurkat T cells were transfected by
electroporation with the full-length and stepwise-deleted frag-
ments of the HIV-1 LTR subcloned upstream of a CAT re-
porter gene (56). After a 24-h incubation, cells were induced
with 10 ng of TNF per ml for 16 h, harvested, and assayed for
CAT activity. The results of these experiments (Fig. 1A) define
a promoter fragment between nucleotides291 and265 that is
necessary for the response to TNF. This fragment contains the
39 kB site and the most 59 Sp1 site of the LTR. This result was
in agreement with a recent report that also pointed out the
necessity of this promoter region for TNF induction of HIV-1
LTR-mediated transcription (50). The deletion of promoter
sequences between positions 2121 and 291 (including the 59
kB site) resulted in reductions of basal and TNF inducibility.
Using oligonucleotide probe LTR A from the TNF-respon-
sive sequence in the HIV LTR, we investigated whether spe-
cific protein complexes would bind this DNA element. Jurkat
T cells, which carry mutant p53 (11), were incubated for 30 min
in the presence (10 ng/ml) or absence of TNF, and then nu-
clear extracts were prepared and assayed by EMSA. Two TICs
(TIC 1 and TIC 2) were observed (Fig. 1B). Addition of the
protein synthesis inhibitor cycloheximide did not inhibit the
formation of these complexes, indicating that TNF-induced
posttranslational modifications on preformed factors were re-
sponsible for their formation. Similar results were obtained
following treatment of Jurkat cells with a mitogen (phytohem-
agglutinin) (data not shown). Here, we focused our attention
on the TNF induction of Jurkat cells.
To determine the specificities of the TICs, we performed
oligonucleotide competition EMSAs. The competition assays
demonstrated that only probes LTR A (Fig. 1C, lane 3) and
LTR B (Fig. 1C, lane 4) were able to specifically compete for
TIC 1 and 2. A probe containing a kB site (lane 2) had no
effect, indicating that NF-kB is not present in the TICs. The
absence of NF-kB complexes can be explained by the lack of a
59 nucleotide necessary for this factor to bind the LTR A
probe. Distinct complexes containing immunoreactive p65
NF-kB were observed with probes containing additional up-
stream sequences (data not shown). Interestingly, both the
LTR A and B probes overlap in the sequence CAGGGAGG
CGTGGCCTG that contains a nonconsensus Sp1 binding site
(underlined), suggesting that Sp1 is the transcription factor
responsible for the TICs. In order to address this point, we
performed methylation interference footprinting and UV
cross-linking on the major TIC, TIC 1.
The methylation interference data shown in Fig. 2A and B
identified a protein binding site (GCGTGGCCT) that partially
overlapped the right flank of the Sp1-like binding site. A de-
tailed examination of this DNA binding site shows that it does
not resemble the footprinting of the Sp1 family of transcription
factors, but it shows significant homology to the p53 RGC
consensus element (Fig. 2B). Further evidence for the identi-
fication of a novel TNF-responsive element was elucidated
through UV cross-linking experiments. In these experiments, a
thymidine at position 11 in the LTR B probe was replaced by
BrdU (probe LTR B-UV1). The probe was allowed to interact
with nuclear extracts of TNF-incubated Jurkat cells, UV cross-
linked for 15 min at 312 nm, and resolved by EMSA as de-
scribed above. The upper TIC band was then isolated, and the
DNA-protein complex was electrophoresed in an SDS–10%
acrylamide gel (Fig. 2C). This protein-DNA complex pre-
sented a mobility of 60 kDa. Since probe LTR B-UV1 exhib-
ited an apparent molecular mass of 5 to 10 kDa (data not
shown), this experiment indicated that TIC 1 contains a pro-
FIG. 1. (A) Identification of HIV LTR promoter region responsive to TNF.
Jurkat T cells (5 3 106 cells per condition) were transfected by electroporation
with 20 mg of the indicated stepwise-deleted fragments of the HIV-1 LTR
upstream of a CAT reporter gene plasmid. A map of the region is inset. After a
24-h incubation, samples were divided in two and incubated in the absence of or
presence of 10 ng of rTNF-a per ml for 16 h. After incubation, the cells were
harvested and assayed for CAT activity. CAT activity was normalized to the basal
activity of the 2494,1232 HIV LTR CAT construct (2 to 5% CAT conversion;
open bar). Data represent the means and standard deviations for three indepen-
dent experiments. (B) Gel shift mobility assay showing complexes bound to the
LTR A sequence with nuclear extracts of TNF-induced Jurkat cells. Jurkat
T-leukemia cells cultured in RPMI 1640 medium with glutamine, 2% fetal calf
serum and penicillin-streptomycin were resuspended in new media at 1 3 106
cells per ml in the absence (2TNF) or presence (1TNF) of 10 ng of rTNF-a per
ml and incubated for 30 min. Cells were then centrifuged and processed for the
preparation of nuclear extracts. Five-microgram aliquots of extracts were assayed
by EMSA, with 0.2 ng of the LTR A sequence used as a probe and 1 mg of
poly(dIdC) z (dIdC). (C) EMSA competition assay with TNF-induced nuclear
cell extracts and the LTR A probe. Two-microgram aliquots of 30-min 10-ng/ml
TNF-induced nuclear extracts were assayed by EMSA with 0.2 ng of LTR A
probe and 5 mg of poly(dIdC) z (dIdC). Competition for binding of nuclear
factors to the LTR A probe was performed with 40 ng of the following probes:
p53kB (lane 2), LTR A (lane 3), LTR B (lane 4), IC (lane 5), RGC (lane 6),
MCK (lane 7), MgBH (lane 8), SRE (lane 9), and MRE (lane 10). For a
description of these oligonucleotides, see Materials and Methods.
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tein of a molecular mass of 50 to 55 kDa. Since Sp1 has a
molecular mass of 95 to 105 kDa, this result proved that Sp1 is
not the protein binding to the site in these assays. Also probe
IC (Fig. 1C, lane 5) containing the Sp1 site in the major
histocompatibility complex class II invariant chain promoter
did not compete for factor binding.
Identification of a proliferative (antibody 240-positive) p53
binding site in the HIV LTR. The presence of p53 in the TICs
was demonstrated in a number of experiments. In an EMSA
(Fig. 3A), formation of TIC 1 was blocked by incubation of the
extracts with a monoclonal antibody (PAb 240) against p53.
PAb 240 recognizes the proliferative (mutant-like) p53 confor-
mation. In addition, PAb 240 partially blocked the formation
of TIC 2. As a control, we found that PAb 240 had no effect on
NF-kB binding in an EMSA using a kB probe (data not
shown). Antibodies PAb 1801 (recognizing denatured p53) and
PAb 1620 (recognizing the antiproliferative conformation)
were not able to block p53 binding to the LTR A probe. An
anti-Sp1 antibody showed no effect on the LTR A TICs in
these assays (data not shown). However, Sp1 complexes were
optimally detected when the binding reaction mixture con-
tained 5 mM MgCl2, no EDTA, and low NaCl concentrations
and when extracts were prepared from cells cultured at high
density (0.53 106 to 13 106 cells per ml [data not shown]). An
EMSA competition experiment using nuclear extracts from
TNF-induced Jurkat cells, an LTR B probe, and a 500-fold
excess of oligonucleotides LTR B, LTR B with a mutation in
the GCGTGGCCT p53 site (Sp1 site), LTR B with a mutation
in the GGGCGG Sp1 site (p53 site), and RGC is shown in Fig.
3B. The LTR B and p53 site, but not the Sp1 site and RGC,
oligonucleotides were able to compete with the LTR B probe
for TIC formation. This experiment indicated that the com-
plexes identified by anti-p53 PAb 240 bind specifically to the
GCGTGGCCT site. Competition with an LTR B oligonucle-
otide with a mutation in the GGGAGG Sp1 site did not show
any difference from the native sequence in the TIC competi-
tion (data not shown). These experiments further confirmed
that the TIC contained a factor that does not belong to the Sp1
family.
FIG. 2. (A) Methylation interference footprinting of TIC 1 with LTR A
probe. LTR A probes were labeled with [g-32P]ATP on the coding or noncoding
strands, annealed with their respective nonlabeled complementary strands, par-
tially methylated, and used in a 10-fold scale-up EMSA with 45-min 10-ng/ml
TNF-induced Jurkat nuclear extracts. TIC 1 (lanes B) and free DNA (lanes F)
were excised and treated as indicated in Materials and Methods. The unused
methylated probes were utilized for the G ladders (lanes G). Binding sites are
indicated by lines above the nucleotide sequences. (B) Comparison of the meth-
ylation interference footprints of TIC 1 in LTR A (HIV) and wild-type p53 in the
RGC sequence (RGC) (32). Partial interference (open circles) and complete
interference (closed circles) are indicated. (C) Cross-linking of TIC 1. A 10-fold
scale-up EMSA was prepared with TNF-induced nuclear extract and the LTR
A-UV probe. DNA-protein complexes were UV irradiated, and the reaction
mixtures were loaded onto 3.9% polyacrylamide gels and run as indicated in
Materials and Methods. TIC 1 was excised and loaded onto an SDS–10% PAGE
gel. Molecular size markers (in kilodaltons) are shown on the left.
FIG. 3. (A) EMSA-antibody blocking experiment characterizing proteins
binding LTR A probe in TNF-induced nuclear extracts. Gel shift reactions were
prepared as described in the legend for Fig. 1B, the anti-p53 antibodies indicated
above the lanes were added, and the mixtures were incubated for 45 min before
loading. (B) EMSA competition experiment with TNF-induced extracts and 0.2
ng of LTR B probe. Extracts were incubated with a 500-fold excess of the
oligonucleotide competitors indicated above the lanes. The Sp1 site and p53 site
oligonucleotides are LTR B sequences with mutations in the p53 and Sp1 sites,
respectively (see Materials and Methods). (C) Western blot indicating the pres-
ence of p53 in biotin-LTR A affinity-purified Jurkat nuclear extracts. TNF-
induced nuclear extracts (100 mg) were incubated with 100 ng of a biotinylated
LTR A probe in the presence of 100 mg of poly(dIdC) z (dIdC) for 20 min at
room temperature. Streptavidin MagneSphere beads (150 ml) were added, and
the mixture was incubated for an additional 15 min prior to precipitation through
a magnetic field. The pellet was resuspended in 250 ml of PBS with 10 mg of
poly(dIdC) z (dIdC) and reprecipitated. The second pellet was then boiled in
SDS-PAGE loading buffer, and the presence of p53 was determined by Western
analysis with PAb 1801 at a 1:500 dilution. (D) Western blot of biotin-LTR B
affinity-purified p53 from TNF-induced Jurkat nuclear extracts. Biotin-LTR B
(p53m) is a biotinylated LTR B oligonucleotide with a mutated p53 site. The
purification and Western blot were carried out as described for panel C. (E) UV
cross-linking–immunoprecipitation experiment showing p53 interaction with the
LTR A probe. Tenfold scale-up EMSA reaction mixtures were prepared as
described above with probe LTR A-UV and were irradiated for 20 min at room
temperature with 312-nm UV light. Immunoprecipitation buffer (250 ml) was
added, and immunoprecipitations were carried out as described in Materials and
Methods. Several antibodies were employed, as indicated above the gel. (F)
Oligonucleotide competition and UV cross-linking–immunoprecipitation exper-
iment showing specific p53 interaction with the LTR B probe. Nuclear extracts
from TNF-induced Jurkat cells were preincubated with a 500-fold excess of the
oligonucleotides indicated above the lanes before a final incubation with an LTR
B probe. The p53 site and Sp1 site oligonucleotides are as described for panel B.
The reactions were carried out as described for panel E.
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To obtain further evidence of the presence of p53 in the
TICs, two different approaches were taken. First, nuclear ex-
tracts from TNF-treated Jurkat cells were incubated with an
LTR A (Fig. 3C) or an LTR B (Fig. 3D) probe linked to biotin.
Following washing, the probe and potentially associated pro-
teins were precipitated with streptavidin-magnetic beads. The
presence of p53 in the precipitates was demonstrated by SDS-
PAGE and Western analysis with antibody 1801. A nonbioti-
nylated DNA control probe demonstrated the specificity of the
reaction with the LTR A probe (Fig. 3C). In another experi-
ment (Fig. 3D), a second LTR B biotinylated probe with a
mutation in the GCGTGGCCT site (biotin-LTR B 53m) was
used. This probe failed to precipitate p53. A second approach
utilized UV cross-linking of TNF-induced Jurkat cell nuclear
extracts to a radiolabeled LTR A probe with a BrdU-for-T
substitution at position 25 followed by precipitation of the
protein-DNA complex with monoclonal antibodies against p53
(Fig. 3E). Antibody PAb 240, but not PAb 1620, was able to
specifically recognize p53 in these complexes. Incubation of the
cells with TNF increased the amount of PAb 240-positive p53-
DNA complex. Addition to the nuclear extracts of 5 mg of
recombinant baculovirus-expressed p53 overcame PAb 240 in-
teraction with endogenous p53. These results and those shown
in Fig. 2 indicated that p53 is present in the TICs and that
interaction of this protein with the HIV LTR element is ac-
companied by the presentation of the PAb 240-positive (pro-
liferative) epitope of the protein. Also, the presence of p53 and
the specificity of its interaction to the LTR probes were dem-
onstrated in an experiment where nuclear extracts from TNF-
induced Jurkat cells were cross-linked to an LTR B probe with
a BrdU-for-T substitution at position 11. Prior to the addition
of the probe, the extracts were incubated with a 500-fold excess
of the LTR B native or mutant oligonucleotides used for the
experiment shown in Fig. 3B. The result, which is shown in Fig.
3F, indicated that p53 is specifically bound to the GCGTG
GCCT site in these extracts. In several competition experi-
ments, the addition of a 200- to 500-fold molar excess of Sp1
containing oligonucleotides (Fig. 1C, lane 5; Fig. 3B, Sp1 site;
Fig. 3F, Sp1 site) produced a decrease in p53-LTR probe
interaction. Also, in experiments with purified proteins, p53
was unable by itself to bind to the LTR probes unless tran-
scription factor Sp1 was provided in the binding reaction (data
not shown) (see Discussion).
Experiments of oligonucleotide competition EMSA using
the LTR A probe showed that the p53 protein present in the
TICs does not recognize reported p53 binding sites. Figure 1
shows that probes RGC (lane 6) (32); MCK, containing the
p53 binding site in the muscle-specific creatine kinase gene
(71) (lane 7); and MgBH, another consensus p53 binding site
(23) (lane 8), were unable to compete for binding of the TICs
on the LTR A probe. Thus the TNF-induced p53 complex does
not recognize previously identified p53 DNA binding sites.
TNF induction did not modify the amount of Jurkat p53 ca-
pable of binding to an RGC probe (data not shown). These
results indicate that two different pools of p53 may be present
in Jurkat cells. One of these pools is represented by the anti-
proliferative p53 that may not be responsive to growth factors
or G0/G1-acting cytokines, as would be expected of a transcrip-
tion factor which functions at the G1/S boundary.
TNF induces the antibody 240-positive p53 epitope. The
detection of PAb 240-reactive p53 in the TICs suggested that
the appearance of this epitope can be induced by incubation
with TNF. To directly address this question, Jurkat T cells were
labeled with [35S]methionine and were stimulated with TNF.
Interestingly, the PAb 240-positive p53 form was induced by
incubation with TNF, as indicated by immunoprecipitation ex-
periments (Fig. 4). Little or no change was observed when
antibody PAb 1620 was used. This result was in agreement with
our observation that no change in binding to p53 consensus
sites is induced by TNF and further suggests the existence of
two different pools of p53. Induction of the PAb 240 epitope
has been demonstrated previously in normal lymphocytes in-
cubated in the presence of the T-cell receptor activator phy-
tohemagglutinin (73).
TNF-responsive element in HIV LTR is a target for mutant
(proliferative) p53. To define the potential role of the prolif-
erative p53 binding site in the HIV LTR, a series of deletion
mutants of the HIV LTR were tested in cotransfection studies
with expression vectors encoding either the wild type or a
tumor-promoting mutant, p53 143ala, under the transcrip-
tional control of a CMV promoter. The p53 143ala mutant was
used because it has been shown that this p53 form is able to
transactivate the HIV LTR and other promoters such as the
proliferating cell nuclear antigen (PCNA) promoter that do
not contain consensus p53 binding sites (16). These experi-
ments were done with Jurkat cells and with Akata B cells,
which do not contain the p53 gene. In Akata cells, overexpres-
sion of wild-type p53 had a minor repressive effect on all the
promoter fragments of the HIV LTR (Fig. 5A). However, p53
143ala was able to strongly transactivate HIV LTR expression.
A similar result was obtained with the p53 248trp transforming
mutant form (data not shown). Deletion of the promoter se-
FIG. 4. Immunoprecipitation of PAb 16201 and 2401 p53 after TNF induc-
tion. Jurkat cells (23 107) were incubated for 1 h in methionine-free RPMI 1640
medium with 0.5 mCi of [35S]methionine per ml and 5 mg of cycloheximide per
ml and in the presence (10 ng/ml) or absence of rTNF-a. Extracts were prepared
for immunoprecipitations with anti-p53 antibodies and analyzed as indicated in
Materials and Methods.
FIG. 5. (A) Transient transfection assay showing the effects of p53 and mu-
tant p53 form (143ala) on a CAT reporter plasmid containing HIV LTR deletion
mutations. Akata cells were cotransfected by electroporation with 10 mg of the
indicated stepwise-deleted fragments of the HIV-1 LTR and 3 mg of a CMV-
driven expression vector containing wild-type p53 sequences (53), 53 143ala
(53m), or no insertion. Cells were incubated for 48 h, and CAT activity was
measured as indicated in Materials and Methods. CAT activity was normalized
to the basal expression level of the 2494,1232 HIV LTR CAT construct (open
bar). The data represent the means and standard deviations for three indepen-
dent experiments. (B) Effects of p53 on the transcriptional activity driven by a
2121,120 HIV LTR CAT reporter plasmid (2121,120) in Jurkat cells. Cells
were cotransfected, and CAT activity was assayed as described above. The basal
expression level of the 2121,120 HIV LTR construct is shown as an open bar.
The data represent the means and standard deviations for three independent
experiments.
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quences that contain the p53 site (from nucleotide 291 to
265) drastically decreased transactivation by p53 143ala. The
deletion mutations of the HIV LTR were mapped with the
p53-responsive fragment in the same area where we initially
identified the HIV LTR TNF responsiveness. Intriguingly, in
Jurkat cells, a positive effect was obtained with both the wild-
type and mutant p53 forms (Fig. 5B). 53D, a p53 expression
vector that contains a 30-amino-acid deletion (position 347 to
377) in the carboxy-terminal domain, did not effectively trans-
activate the HIV LTR reporter construct. This deletion is
located outside the core binding domain of p53 (49) in a region
that contains the nuclear localization sequence and that has
been implicated in the ability of p53 to oligomerize and to
interact with other proteins (51). Transfection of Sp1 increased
HIV LTR CAT expression by sixfold, indicating that under our
conditions the HIV LTR Sp1 sites were not saturated. How-
ever, only an additive effect was observed with cotransfections
of Sp1 with p53 expression vectors in Jurkat cells (data not
shown).
To obtain independent evidence of the importance of the
HIV p53 site, cotransfection experiments with a site-directed
HIV LTR mutant construct were performed. CAT reporter
vector HIV LTR 53D contains point mutations in the p53 site
(see Materials and Methods). These mutations substantially
reduced TNF induction of the HIV LTR (Fig. 6A). Also, the
results shown in Fig. 6B revealed that these mutations de-
creased the ability of mutant p53 143ala to transactivate the
HIV LTR. However, they could not completely block all the
transactivation by p53, indicating that other p53-responsive
elements may be present in upstream sequences. While we
were preparing our manuscript, a report indicating that mutant
p53 forms are able to transactivate the HIV LTR was pub-
lished (57). No sequence-specific element was identified in that
study, and its authors hypothesized that mutant p53 transacti-
vation was mediated by interaction with the basic transcription
machinery. In contrast, our results show the absence of acti-
vation by mutant p53 of the 265,120 HIV LTR construct,
which lacks the p53 binding site but contains two consensus
Sp1 binding sites and the HIV LTR TATA box (Fig. 5A). Also,
the results obtained with HIV LTR 53D (Fig. 6B) indicate that
the p53 site is necessary for full activation of the HIV LTR by
the proliferative p53 forms. Importantly, Duan et al. (17) have
recently shown that overexpression of wild-type p53 inhibited
HIV-1 LTR-mediated transcription and that the mechanism of
that repression is mediated by LTR sequences from positions
2117 to 265. Additionally, it was shown that mutant forms of
p53 strongly stimulated HIV replication (17).
In order to determine more accurately the site specificity of
p53 mutant transactivation, we used minimal elements con-
taining the LTR A sequence subcloned upstream of a heter-
ologous promoter, E1B TATA (50). As shown by Fig. 7, this
minimal promoter construct (53-E1B TATA) was activated
10-fold by p53 143ala, yet no effect was observed with a con-
struct containing a mutated p53 site (53D-E1B TATA). This
result demonstrated that transactivation by the p53 mutant
form is site dependent. As expected, a small repressive effect
was found with the cotransfection of wild-type p53 and 53-E1B
TATA in Akata cells (Fig. 7). Somewhat surprisingly, wild-type
p53 was able to achieve fourfold transactivation of the 53-E1B
TATA construct in Jurkat cells (see Discussion). Cotransfec-
tion of a multimer p53 consensus site (PG13) in Akata cells
with the expression construct containing wild-type p53 clearly
resulted in high levels of CAT activity, while mutant form
143ala had no effect (Fig. 7). Also, murine sarcoma virus LTR-
driven expression vectors containing wild-type p53 and a num-
ber of mutant p53 proteins (including Val-135, His-175, Trp-
248, and His-273 sequences) were able to transactivate this
minimal promoter element in Jurkat cells (data not shown).
These results correlate with those of the in vitro binding ex-
periments and establish a transcriptional base for describing
the functional difference between the proliferative and anti-
proliferative forms of p53.
DISCUSSION
This paper focuses on two major findings: the identification
of a novel binding site in the HIV LTR for the proliferative
form of p53 and the role of this site in the induction of HIV
gene expression by TNF. Evidence that the TNF-inducible
binding activity contains p53 is based on methylation interfer-
FIG. 6. Effects of the mutation of the p53 binding site on the transactivation
of the HIV LTR by TNF (A) and p53 143ala (p53m) (B). Jurkat (A) or Akata
(B) cells were transfected with 10 mg of a native 2494,1232 HIV LTR CAT
reporter (HIV LTR) or a site-directed mutated reporter (HIV LTR 53D). Trans-
fections, incubations, and CAT assays were performed as described for Fig. 5.
Jurkat cells were transfected with 5 mg of HIV LTR CAT reporter vectors,
incubated for 24 h, and then induced with 10 ng of rTNF-a per ml for an
additional 16 h. CAT activity was measured as indicated in Materials and Meth-
ods. Activity was related to basal expression of the wild-type vector (open bar).
Akata cells were cotransfected with 5 mg of the native and mutated HIV LTR
CAT reporters and 3 mg of CMV-p53 143ala expression vector. Cells were
incubated for 48 h, harvested, and assayed for CAT activity as indicated in
Materials and Methods. The data in panel A and B represent the means and
standard deviations for three independent experiments.
FIG. 7. Transient transfection assay showing the effects of p53 and p53
143ala (53m) on minimal transcriptional elements containing the p53 binding site
in the HIV LTR (53-E1B TATA), a mutated HIV p53 site (53D-E1B TATA),
and a consensus wild-type p53 binding site (PG13) in Akata cells. Expression
vectors (3 mg) and 10 mg of reporters were used. Transfections, incubation, and
CAT assays were carried out as described for Fig. 5. CAT activity was normalized
to the basal expression levels of the 53-E1B TATA and PG13 vectors (open bars;
1 to 4% CAT conversion). These data represent the means and standard devi-
ations for three independent experiments.
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ence patterns and UV cross-linking (Fig. 2 and 3), EMSAs
(Fig. 3), and transfection experiments (Fig. 5 to 7). Evidence
that the p53 protein is present in the proliferative conforma-
tion is based on the results of multiple experiments (as dis-
cussed below).
TNF is a multifunctional cytokine secreted primarily by mi-
togen-activated macrophages that has a wide range of biolog-
ical activities. TNF can induce both apoptotic and necrotic
forms of cell death (15, 34). The expression of this cytokine is
also associated with activation of the immune system (29). It
has recently been shown that TNF can enhance the prolifera-
tion of thymocytes and T cells (58). Other reports have shown
that TNF may have a bidirectional effect, with the increase or
inhibition of T-cell proliferation depending on the concentra-
tion of mitogenic costimulators (27). These studies show that
TNF has unique regulatory effects on both T-cell growth and
differentiation processes. It has been demonstrated that the
two different receptors of TNF, TNF-R1 and TNF-R2, medi-
ate distinct cellular responses (58, 59). TNF-R2 initiates signals
for the proliferation of T cells, whereas TNF-R1 initiates sig-
nals for cytotoxicity. However, it is still unclear how the two
receptors initiate distinct signaling pathways since both recep-
tor types are expressed simultaneously in multiple cell lines
(59). Thus, our studies suggest that one mechanism whereby
TNF can control cell growth is through the modulation of p53
activity.
Although the TNF-responsive element in the HIV LTR is
bound by endogenous p53 when Jurkat cells are induced by
TNF, we did not see binding to this element with recombinant
wild-type or mutant p53 unless the transcription factor Sp1 was
provided (25). Thus, it is possible that p53 is converted to a
proliferative conformation through an interaction with Sp1.
Interestingly, it has been reported that a physical interaction
between p53 and Sp1 can occur (6). Cooperativity between p53
and Sp1 for DNA binding was suggested by EMSA and UV-
cross-linking oligonucleotide competition experiments (Fig. 3B
and F). Current experiments in our laboratory are focused on
the potential role of ternary complexes involving p53, Sp1, and
NF-kB family members in the regulation of HIV LTR-medi-
ated expression. As described above, our data strongly suggest
that the form of p53 that binds to the HIV LTR is the so-called
proliferative form. Consistent with the proposal that prolifer-
ative p53 binds to this element are the observations that anti-
bodies that recognize proliferative forms of p53 recognize the
p53-DNA complex (Fig. 3) and that oncogenic forms of p53
are able to specifically activate gene expression through the
HIV LTR p53 site (Fig. 5 to 7). Furthermore, our data dem-
onstrate that this inducible form of p53 binds to DNA elements
different from, although related to, those to which recombinant
p53 binds (Fig. 1 and data not shown).
The identification of this novel p53 site may have implica-
tions for the understanding of the mechanism of replication of
HIV. Leonard et al. (35) demonstrated that deletion of either
the TAR element or the region containing the p53 and Sp1
sites, but not of the kB sites, blocks the ability of HIV-1 to
replicate in peripheral blood lymphocytes. In addition, TNF
has been shown to activate HIV replication in both T and
mononuclear cells (5). Parrott et al. (48) and Ross et al. (53)
demonstrated that deletion of the p53 and Sp1 binding region
of the HIV LTR had no effect on HIV-1 replication in blood
lymphocytes. However, this deletion markedly delayed basal
replication and TNF-induced replication in T-cell lines. Thus,
it is possible that a transcription factor like p53 which has been
shown to be highly expressed in replicating normal human
lymphocytes (73) has an important role in HIV replication in
vivo. Specifically, it appears that the virus utilizes the so-called
proliferative form of p53. p53 may be also important for the
replication of the virus in other cells, such as macrophages. In
addition, p53 may play a more-critical role in HIV biology in
the context of infection within the host and its role may not be
fully apparent in experiments performed in tissue culture.
Also, the variability of the status of the p53 gene may help to
explain the diverse levels of HIV-1 expression obtained in
different lymphocyte cell lines. Obviously, an analysis of mu-
tations of the HIV LTR p53 site is necessary to elucidate the
role of this protein in the replication of the virus. Interestingly,
a recent publication (17) suggested a role for p53 in the reg-
ulation of HIV gene expression and viral replication. A region
encompassing the p53 site identified in our work was shown to
mediate repression of HIV LTR-directed gene expression by
wild-type p53. Consistent with our data, a mutated form of p53
was shown to strongly activate viral replication. We propose
that mutant forms of p53 activate viral gene expression
through some type of direct interaction with the p53 site iden-
tified in our study. In addition, it is possible that other as-yet-
unidentified p53 sites exist on the HIV LTR. Furthermore, we
suggest that normal p53 plays an important role in the activa-
tion of HIV gene expression through the activation of the
so-called proliferative form.
Using a series of deletion mutants of the HIV LTR, we
mapped the location of a TNF-responsive element in the LTR
(Fig. 1). This promoter fragment contains the binding sites of
several transcription factors, including NF-kB and Sp1. Nu-
merous reports have indicated the role of NF-kB and Sp1 in
the TNF induction of LTR-mediated expression. The kB ele-
ments are required for HIV LTR-inducible expression in ac-
tivated T cells and mature monocytes (43), while Sp1 is
thought to regulate the basal level of transcription (30). Inter-
estingly, of the three HIV Sp1 sites described by Jones et al.
(30), the most 59 site was not necessary for Sp1 transactivation
of the HIV LTR. These authors concluded that the more 39
Sp1 sites were primarily responsible for promoter strength,
whereas binding to the most 59 Sp1 site was unimportant for
stimulation of RNA synthesis. It has been shown previously
that an interaction between NF-kB and Sp1 is critical for
activation of gene expression directed by the HIV LTR (50),
and a cooperative interaction between NF-kB and Sp1 was
observed. This functional interaction occurs in the region iden-
tified as controlling the p53 response. Thus, it is possible that
the p53-mediated pathway reported here involves a pathway
for HIV LTR-directed gene expression that is distinct from
that utilized by NF-kB and Sp1. Alternatively, complex pro-
tein-protein interactions that involve NF-kB, p53, and Sp1 may
form on the LTR. It is also likely that some cellular promoters
contain Sp1-p53 composite sites. This hypothesis is most inter-
esting when promoters that have been shown to be transacti-
vated by transforming mutant forms of p53 and yet do not
contain known p53 binding sites are considered. Some exam-
ples of these genes are the PCNA (16) and MDR1 genes (12).
The case of the MDR1 gene is particularly important because
MDR1 expression is induced by TNF (8) and the promoter
sequences do not contain kB sites but possess a functional Sp1
site (14).
Several studies have shown that p53 gene expression is
strongly induced in lymphocytes after stimulation by mitogens
(38, 40, 60). Also, experiments of microinjection of monoclonal
anti-p53 antibodies (37) and antisense p53 (55) demonstrated
that p53 is required for the induction of cell proliferation by
growth factors. The data reported here suggest that p53 may
play a role as a positive regulator of the G0/G1 transition, as
suggested by previous observations (reference 62 and refer-
ences therein). It has been proposed that p53 can exist in two
3456 GUALBERTO ET AL. MOL. CELL. BIOL.
distinct functional forms, the so-called antiproliferative form
and the proliferative form (39, 62). Some of the antibodies that
recognize the proliferative form of p53 also recognize mutant
(oncogenic) forms of p53. Thus, it is possible that a conforma-
tional change in p53 is associated with the proliferative func-
tions of p53 and that certain mutant forms of p53 are unable to
adopt the antiproliferative conformation and thus may func-
tion exclusively in a proliferative role (51, 62). Presumably
then, proliferative p53 functions as a transcription factor by
directing gene expression through a different DNA binding site
than exists for nonproliferative p53. The site within the HIV
LTR site likely represents a new class of p53 binding sites that
functions in a proliferative manner. Genes that contain sites
functionally related to the HIV LTR p53 site would be regu-
lated in a proliferative manner by p53 (as discussed below),
and those that contain sites for nonproliferative p53 would
function to inhibit cell proliferation. Recently, it was shown
that the p21/Waf1/Cip1 gene is regulated by p53 (19, 26, 70).
The protein encoded by p21/Waf1/Cip1 negatively regulates
cyclin-cdk activity, and thus the loss of wild-type p53 function
and the loss of expression of this protein may explain the
growth suppressor function of p53. Thus, deletion of wild-type
(nonproliferative) p53 in tumor cells would lead to the loss of
the growth suppressor function of p53. Mutations that gener-
ate oncogenic forms of p53 (46) may lead to gene-specific
transcription mediated by sites similar to the one identified in
the HIV LTR. An important question is whether mutant forms
of p53 can bind to DNA in a specific fashion. Several of the
mutant forms of p53 exhibit mutations in amino acids that are
known to critically contact residues in the p53 consensus site
(13). Thus, the ability of mutant p53 to bind to nonconsensus
DNA sequences may be explained by several possibilities. A
mitogen-triggered posttranslational modification and/or inter-
action with other proteins (potentially Sp1) may restructure
the mutant form of p53 such that it can make critical DNA
contacts. Alternatively, certain DNA sites (such as the site in
the HIV LTR) that are not identical to a p53 consensus site
may bind to mutant p53 forms because an amino acid-nucle-
otide contact essential for p53-consensus DNA interaction is
not found in the mutant p53-nonconsensus DNA complex. A
combination of these two possibilities may allow for potential
high-affinity interaction between mutated forms of p53 and
certain DNA elements.
What functions to convert p53 from the nonproliferative to
the proliferative form? p53 has a short half-life, 6 to 10 min, in
proliferating T cells (52). This extraordinarily rapid turnover
indicates that p53 has a tightly regulated function in T cells.
Recently, Appella and coworkers indicated that phosphoryla-
tion at specific sites regulates p53 ability to induce growth
arrest and to associate with the simian virus 40 T antigen (22,
64). It is feasible that posttranslational modifications are nec-
essary to regulate p53 transcriptional functions. Consistent
with this idea is our observation that the inducible form of p53
can be activated in the presence of protein synthesis inhibitors.
It is also possible that signal transduction events lead to the
differential association of p53 with modulatory proteins. For
example, MDM2 is a p53-associated protein that functions to
inhibit presumably the nonproliferative functions of p53. Since
our data demonstrate a role for Sp1 in the proliferative func-
tions of p53, a signal transduction event may lead to the mod-
ification of p53 with its subsequent dissociation from MDM2
and its association with Sp1. The p53-MDM2 interaction do-
mains have been recently mapped to the N-terminal domains
of both proteins (9), and the p53 N-terminal domain has been
shown to contain its activation domain (45). Furthermore,
studies on MDM2 gene expression demonstrate that it is reg-
ulated by the levels of p53 protein (69). These results indicate
that p53 regulates MDM2 expression and that MDM2 regu-
lates p53 transcriptional activity, creating an autoregulatory
feedback loop (69).
Since mutant forms of p53 have lost the ability to bind to
consensus p53 elements, these mutations may represent an
important gain-of-function phenotype that is operative in the
oncogenic roles of these proteins. Intriguingly, in our transfec-
tion experiments with Akata cells, mutant p53, but not wild-
type p53, was able to transactivate the HIV LTR; however, in
Jurkat cells, a positive effect was observed with both wild-type
and mutant p53 forms (Fig. 7). It is unclear why the wild-type
p53 form can activate the HIV LTR in Jurkat cells, although
several explanations can be proposed. It is known that mutant
forms of p53 can oligomerize with wild-type p53 and alter its
conformation (39). Thus, the presence of the endogenous p53
mutant in Jurkat cells (11) may alter the effect of the trans-
fected wild-type p53, leading to activation of gene expression.
Consistent with this point is the observation that only mutated
p53 can stimulate gene expression in Akata cells, which do not
express endogenous p53. Another explanation of why wild-type
p53 can activate HIV LTR-directed gene expression is that
Jurkat T cells may have an activated signal transduction path-
way that leads to the conversion of wild-type (nonproliferative)
p53 to a proliferative form.
In summary, the interpretation of the data presented here is
that proliferative conformations of wild-type p53 exhibit
growth-regulatory properties by interacting with sites specific
for the proliferative forms. It is possible that the gain-of-
growth properties of tumor-promoting p53 forms are mediated
by their transcriptional activities. p53 mutant forms would then
be expected to be transcriptionally active because they mimic
specific functions of a wild-type p53 proliferative conforma-
tion. We hypothesize that proliferative p53 and antiprolifera-
tive p53 recognize different DNA binding sites which can me-
diate proliferative and antiproliferative functions, respectively.
Wild-type p53 may shift from an antiproliferative to a prolif-
erative conformation by TNF or growth factor induction. The
effect of the TNF signal pathway may allow p53 to interact with
other transcription factors, such as Sp1, and facilitate the bind-
ing of these proteins to composite p53-Sp1-responsive DNA
elements. The data also present further evidence that HIV-1
utilizes a pathway for replication that is directly modulated by
the growth status of the cell. It would be interesting to deter-
mine if regulatory proteins of HIV, such as nef or tat, have
effects on this unique transcriptional activation pathway.
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